{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:31:46Z","timestamp":1792024306355,"version":"4.4.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41417-025-00911-x","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:33:25Z","timestamp":1745926405000},"page":"721-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring RNA biology in pseudomyxoma peritonei uncovers splicing dysregulation as a novel, targetable molecular vulnerability"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5942-7768","authenticated-orcid":false,"given":"Mar\u00eda Trinidad","family":"Moreno-Montilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Pedraza-Arevalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Bl\u00e1zquez-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-0168","authenticated-orcid":false,"given":"V\u00edctor","family":"Garc\u00eda-Vioque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Rodr\u00edguez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Valenzuela-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Rufi\u00e1n-And\u00fajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Granados-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ortega-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Alors-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari C.","family":"V\u00e1zquez-Borrego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Romero-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3145-7287","authenticated-orcid":false,"given":"Justo P.","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-3009","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Arjona-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-0095","authenticated-orcid":false,"given":"Alejandro","family":"Ib\u00e1\u00f1ez-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"911_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1245\/s10434-020-08655-8","volume":"28","author":"TDJH Patrick-Brown","year":"2021","unstructured":"Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K. Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method. Ann Surg Oncol. 2021;28:252\u20137.","journal-title":"Ann Surg Oncol"},{"key":"911_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","volume":"47","author":"K Govaerts","year":"2021","unstructured":"Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, et al. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol. 2021;47:11\u201335.","journal-title":"Eur J Surg Oncol"},{"key":"911_CR3","doi-asserted-by":"publisher","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","volume":"156","author":"S Kusamura","year":"2021","unstructured":"Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, et al. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg. 2021;156:e206363.","journal-title":"JAMA Surg"},{"key":"911_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/SLA.0b013e31818eec64","volume":"249","author":"D Baratti","year":"2009","unstructured":"Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249:243\u20139.","journal-title":"Ann Surg"},{"key":"911_CR5","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1245\/s10434-020-09560-w","volume":"28","author":"B Rufi\u00e1n-Andujar","year":"2021","unstructured":"Rufi\u00e1n-Andujar B, Valenzuela-Molina F, Rufi\u00e1n-Pe\u00f1a S, Casado-Adam \u00c1, S\u00e1nchez-Hidalgo JM, Rodr\u00edguez-Ortiz L, et al. From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study. Ann Surg Oncol. 2021;28:2819\u201327.","journal-title":"Ann Surg Oncol"},{"key":"911_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10555-023-10088-0","volume":"42","author":"NW Murage","year":"2023","unstructured":"Murage NW, Ahmed NM, Underwood TJ, Walters ZS, Breininger SP. The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review. Cancer Metast Rev. 2023;42:335\u201359.","journal-title":"Cancer Metast Rev"},{"key":"911_CR7","first-page":"1481","volume":"49","author":"A Arjona-Sanchez","year":"2023","unstructured":"Arjona-Sanchez A, Martinez-L\u00f3pez A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Mart\u00ednez-Torres B, et al. External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2023;49:1481\u20138.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"911_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11154-022-09771-4","volume":"24","author":"R Bl\u00e1zquez-Encinas","year":"2023","unstructured":"Bl\u00e1zquez-Encinas R, Moreno-Montilla MT, Garc\u00eda-Vioque V, Gracia-Navarro F, Alors-P\u00e9rez E, Pedraza-Arevalo S, et al. The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities. Rev Endocr Metab Disord. 2023;24:267\u201382.","journal-title":"Rev Endocr Metab Disord"},{"key":"911_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41580-022-00545-z","volume":"24","author":"LE Marasco","year":"2023","unstructured":"Marasco LE, Kornblihtt AR. The physiology of alternative splicing. Nat Rev Mol Cell Biol. 2023;24:242\u201354.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"911_CR10","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrm3657","volume":"14","author":"DL Makino","year":"2013","unstructured":"Makino DL, Halbach F, Conti E. The RNA exosome and proteasome: common principles of degradation control. Nat Rev Mol Cell Biol. 2013;14:654\u201360.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"911_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0092-8674(00)80542-5","volume":"96","author":"MW Hentze","year":"1999","unstructured":"Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. Cell. 1999;96:307\u201310.","journal-title":"Cell"},{"key":"911_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","volume":"20","author":"T Kurosaki","year":"2019","unstructured":"Kurosaki T, Popp MW, Maquat LE. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat Rev Mol Cell Biol. 2019;20:406\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"911_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczuk\u00f3w O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23:135\u201355.","journal-title":"Nat Rev Cancer"},{"key":"911_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-024-01734-2","volume":"9","author":"Y Tao","year":"2024","unstructured":"Tao Y, Zhang Q, Wang H, Yang X, Mu H. Alternative splicing and related RNA binding proteins in human health and disease. Signal Transduct Target Ther. 2024;9:26.","journal-title":"Signal Transduct Target Ther"},{"key":"911_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41568-024-00750-2","volume":"24","author":"O Anczukow","year":"2024","unstructured":"Anczukow O, Allain FH-T, Angarola BL, Black DL, Brooks AN, Cheng C, et al. Steering research on mRNA splicing in cancer towards clinical translation. Nat Rev Cancer. 2024;24:887\u2013905.","journal-title":"Nat Rev Cancer"},{"key":"911_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1126\/science.adn8105","volume":"386","author":"ME Rogalska","year":"2024","unstructured":"Rogalska ME, Mancini E, Bonnal S, Gohr A, Dunyak BM, Arecco N, et al. Transcriptome-wide splicing network reveals specialized regulatory functions of the core spliceosome. Science. 2024;386:551\u201360.","journal-title":"Science"},{"key":"911_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.bbagrm.2013.03.002","volume":"1829","author":"R Karam","year":"2013","unstructured":"Karam R, Wengrod J, Gardner LB, Wilkinson MF. Regulation of nonsense-mediated mRNA decay: implications for physiology and disease. Biochim Biophys Acta. 2013;1829:624\u201333.","journal-title":"Biochim Biophys Acta"},{"key":"911_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbagrm.2013.01.006","volume":"1829","author":"A Chlebowski","year":"2013","unstructured":"Chlebowski A, Lubas M, Jensen TH, Dziembowski A. RNA decay machines: the exosome. Biochim Biophys Acta. 2013;1829:552\u201360.","journal-title":"Biochim Biophys Acta"},{"key":"911_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12575-024-00239-0","volume":"26","author":"A Romero-Ruiz","year":"2024","unstructured":"Romero-Ruiz A, Granados-Rodr\u00edguez M, Bura FI, Valenzuela-Molina F, Rufi\u00e1n-And\u00fajar B, Mart\u00ednez-L\u00f3pez A, et al. Breaking the Mucin Barrier: A New Affinity Chromatography-Mass Spectrometry Approach to Unveil Potential Cell Markers and Pathways Altered in Pseudomyxoma Peritonei. Biol Proced Online. 2024;26:13.","journal-title":"Biol Proced Online"},{"key":"911_CR20","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.18632\/oncotarget.3198","volume":"6","author":"DL Roberts","year":"2015","unstructured":"Roberts DL, O\u2019Dwyer ST, Stern PL, Renehan AG. Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines. Oncotarget. 2015;6:10786\u2013800.","journal-title":"Oncotarget"},{"key":"911_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nchembio.2007.16","volume":"3","author":"Y Kotake","year":"2007","unstructured":"Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007;3:570\u20135.","journal-title":"Nat Chem Biol"},{"key":"911_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111318","volume":"406","author":"A Rossi","year":"2025","unstructured":"Rossi A, Biancalana L, Van\u010do J, Malina T, Zacchini S, Dvo\u0159\u00e1k Z, et al. The effect of a varying pyridine ligand on the anticancer activity of Diiron(I) bis-cyclopentadienyl complexes. Chem Biol Interact. 2025;406:111318.","journal-title":"Chem Biol Interact"},{"key":"911_CR23","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1158\/1078-0432.CCR-23-4072","volume":"30","author":"J Mart\u00ednez-Quintanilla","year":"2024","unstructured":"Mart\u00ednez-Quintanilla J, Cabot D, Sabia D, Arqu\u00e9s O, for the PMPnet Group, Verg\u00e9s J, et al. Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. Clin Cancer Res. 2024;30:4082\u201399.","journal-title":"Clin Cancer Res"},{"key":"911_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s13046-021-02153-9","volume":"40","author":"E Alors-Perez","year":"2021","unstructured":"Alors-Perez E, Bl\u00e1zquez-Encinas R, Alcal\u00e1 S, Viyuela-Garc\u00eda C, Pedraza-Arevalo S, Herrero-Aguayo V, et al. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. J Exp Clin Cancer Res. 2021;40:382.","journal-title":"J Exp Clin Cancer Res"},{"key":"911_CR25","doi-asserted-by":"crossref","unstructured":"Vandesompele J, Preter KD, Roy NV, Paepe AD. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genom Biol. 2002;3:90.","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"911_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1761","volume":"14","author":"Z Ding","year":"2023","unstructured":"Ding Z, Meng Y-R, Fan Y-J, Xu Y-Z. Roles of minor spliceosome in intron recognition and the convergence with the better understood major spliceosome. Wiley Interdiscip Rev RNA. 2023;14:e1761.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"911_CR27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ijc.35137","volume":"156","author":"N Lazzari","year":"2025","unstructured":"Lazzari N, Rigotto G, Montini B, Del Bianco P, Moretto E, Palladino F, et al. Stemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei. Int J Cancer. 2025;156:201\u201315.","journal-title":"Int J Cancer"},{"key":"911_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-71","volume":"9","author":"A Amini","year":"2014","unstructured":"Amini A, Masoumi-Moghaddam S, Ehteda A, Morris DL. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects. Orphanet J Rare Dis. 2014;9:71.","journal-title":"Orphanet J Rare Dis"},{"key":"911_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","volume":"33","author":"R Mittal","year":"2017","unstructured":"Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperth. 2017;33:511\u20139.","journal-title":"Int J Hyperth"},{"key":"911_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155129","volume":"254","author":"E Pretzsch","year":"2024","unstructured":"Pretzsch E, Neumann J, Nie\u00df H, Pretzsch CM, Hofmann FO, Kirchner T, et al. Comparative transcriptomic analyses reveal activation of the epithelial-mesenchymal transition program in non-metastasizing low grade pseudomyxoma peritonei. Pathol Res Pr. 2024;254:155129.","journal-title":"Pathol Res Pr"},{"key":"911_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal SC, L\u00f3pez-Oreja I, Valc\u00e1rcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17:457\u201374.","journal-title":"Nat Rev Clin Oncol"},{"key":"911_CR32","first-page":"63","volume":"251","author":"S Pedraza-Arevalo","year":"2023","unstructured":"Pedraza-Arevalo S, Alors-P\u00e9rez E, Bl\u00e1zquez-Encinas R, Herrera-Mart\u00ednez AD, Jim\u00e9nez-Vacas JM, Fuentes-Fayos AC, et al. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors. Transl Res J Lab Clin Med. 2023;251:63\u201373.","journal-title":"Transl Res J Lab Clin Med"},{"key":"911_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.102090","volume":"35","author":"E Alors-P\u00e9rez","year":"2024","unstructured":"Alors-P\u00e9rez E, Pedraza-Arevalo S, Bl\u00e1zquez-Encinas R, Garc\u00eda-Vioque V, Agraz-Doblas A, Yubero-Serrano EM, et al. Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response. Mol Ther Nucleic Acids. 2024;35:102090.","journal-title":"Mol Ther Nucleic Acids"},{"key":"911_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04754-8","volume":"21","author":"R Bl\u00e1zquez-Encinas","year":"2023","unstructured":"Bl\u00e1zquez-Encinas R, Garc\u00eda-Vioque V, Caro-Cuenca T, Moreno-Montilla MT, Mangili F, Alors-P\u00e9rez E, et al. Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery. J Transl Med. 2023;21:879.","journal-title":"J Transl Med"},{"key":"911_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216604","volume":"584","author":"P S\u00e1ez-Mart\u00ednez","year":"2024","unstructured":"S\u00e1ez-Mart\u00ednez P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, Sanchez-Sanchez R, Gonz\u00e1lez-Serrano T, et al. Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1. Cancer Lett. 2024;584:216604.","journal-title":"Cancer Lett"},{"key":"911_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01364-0","volume":"20","author":"G Nogueira","year":"2021","unstructured":"Nogueira G, Fernandes R, Garc\u00eda-Moreno JF, Rom\u00e3o L. Nonsense-mediated RNA decay and its bipolar function in cancer. Mol Cancer. 2021;20:72.","journal-title":"Mol Cancer"},{"key":"911_CR37","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41588-019-0517-5","volume":"51","author":"RGH Lindeboom","year":"2019","unstructured":"Lindeboom RGH, Vermeulen M, Lehner B, Supek F. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat Genet. 2019;51:1645\u201351.","journal-title":"Nat Genet"},{"key":"911_CR38","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.7150\/thno.71100","volume":"12","author":"K Wang","year":"2022","unstructured":"Wang K, Pan S, Zhao P, Liu L, Chen Z, Bao H, et al. PTBP1 knockdown promotes neural differentiation of glioblastoma cells through UNC5B receptor. Theranostics. 2022;12:3847\u201361.","journal-title":"Theranostics"},{"key":"911_CR39","doi-asserted-by":"crossref","unstructured":"Song X, Tiek D, Miki S, Huang T, Lu M, Goenka A, et al. RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma. J Clin Invest. 134:e173789.","DOI":"10.1172\/JCI173789"},{"key":"911_CR40","doi-asserted-by":"publisher","first-page":"5719","DOI":"10.7150\/thno.42010","volume":"10","author":"L Shen","year":"2020","unstructured":"Shen L, Lei S, Zhang B, Li S, Huang L, Czachor A, et al. Skipping of exon 10 in Axl pre-mRNA regulated by PTBP1 mediates invasion and metastasis process of liver cancer cells. Theranostics. 2020;10:5719\u201335.","journal-title":"Theranostics"},{"key":"911_CR41","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1158\/1078-0432.CCR-17-3850","volume":"24","author":"P Bielli","year":"2018","unstructured":"Bielli P, Panzeri V, Lattanzio R, Mutascio S, Pieraccioli M, Volpe E, et al. The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer. Clin Cancer Res J Am Assoc Cancer Res. 2018;24:5422\u201332.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"911_CR42","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/onc.2015.270","volume":"35","author":"S Calabretta","year":"2016","unstructured":"Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V, Capurso G, et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Oncogene. 2016;35:2031\u20139.","journal-title":"Oncogene"},{"key":"911_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nsmb1137","volume":"13","author":"AP Rideau","year":"2006","unstructured":"Rideau AP, Gooding C, Simpson PJ, Monie TP, Lorenz M, H\u00fcttelmaier S, et al. A peptide motif in Raver1 mediates splicing repression by interaction with the PTB RRM2 domain. Nat Struct Mol Biol. 2006;13:839\u201348.","journal-title":"Nat Struct Mol Biol"},{"key":"911_CR44","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1093\/nar\/gkae046","volume":"52","author":"A Wedler","year":"2024","unstructured":"Wedler A, Bley N, Gla\u00df M, M\u00fcller S, Rausch A, Lederer M, et al. RAVER1 hinders lethal EMT and modulates miR\/RISC activity by the control of alternative splicing. Nucleic Acids Res. 2024;52:3971\u201388.","journal-title":"Nucleic Acids Res"},{"key":"911_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25716","volume":"10","author":"Y Dai","year":"2024","unstructured":"Dai Y, Zhang H, Feng S, Guo C, Tian W, Sun Y, et al. SMG9 is a novel prognostic-related biomarker in glioma correlating with ferroptosis and immune infiltrates. Heliyon. 2024;10:e25716.","journal-title":"Heliyon"},{"key":"911_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701454","volume":"12","author":"X Jin","year":"2021","unstructured":"Jin X, Yin J, Zhu H, Li W, Yu K, Liu M, et al. SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt\/\u03b2-Catenin Signaling Pathway in Hepatocellular Carcinoma. Front Pharm. 2021;12:701454.","journal-title":"Front Pharm"},{"key":"911_CR47","doi-asserted-by":"publisher","first-page":"196.e1","DOI":"10.1016\/j.urolonc.2020.10.072","volume":"39","author":"N Amano","year":"2021","unstructured":"Amano N, Matsumoto K, Shimizu Y, Nakamura M, Tsumura H, Ishii D, et al. High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy. Urol Oncol. 2021;39:196.e1\u2013196.e7.","journal-title":"Urol Oncol"},{"key":"911_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2020.05.010","volume":"38","author":"LF Escobar-Hoyos","year":"2020","unstructured":"Escobar-Hoyos LF, Penson A, Kannan R, Cho H, Pan C-H, Singh RK, et al. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell. 2020;38:198\u2013211.e8.","journal-title":"Cancer Cell"},{"key":"911_CR49","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1101\/gad.270645.115","volume":"30","author":"L Fish","year":"2016","unstructured":"Fish L, Pencheva N, Goodarzi H, Tran H, Yoshida M, Tavazoie SF. Muscleblind-like 1 suppresses breast cancer metastatic colonization and stabilizes metastasis suppressor transcripts. Genes Dev. 2016;30:386\u201398.","journal-title":"Genes Dev"},{"key":"911_CR50","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1158\/0008-5472.CAN-20-1233","volume":"80","author":"DM Voss","year":"2020","unstructured":"Voss DM, Sloan A, Spina R, Ames HM, Bar EE. The Alternative Splicing Factor, MBNL1, Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-Induced Stemness. Cancer Res. 2020;80:4681\u201392.","journal-title":"Cancer Res"},{"key":"911_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102129","volume":"35","author":"L Xiao","year":"2024","unstructured":"Xiao L, Sun H, Cheng R, Yang R, Jin X, Xu Z, et al. Functional requirement of alternative splicing in epithelial-mesenchymal transition of pancreatic circulating tumor. Mol Ther Nucleic Acids. 2024;35:102129.","journal-title":"Mol Ther Nucleic Acids"},{"key":"911_CR52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hep.27380","volume":"61","author":"S Sen","year":"2015","unstructured":"Sen S, Langiewicz M, Jumaa H, Webster NJG. Deletion of serine\/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatol Balt Md. 2015;61:171\u201383.","journal-title":"Hepatol Balt Md"},{"key":"911_CR53","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1093\/brain\/awaa273","volume":"143","author":"AC Fuentes-Fayos","year":"2020","unstructured":"Fuentes-Fayos AC, V\u00e1zquez-Borrego MC, Jim\u00e9nez-Vacas JM, Bejarano L, Pedraza-Ar\u00e9valo S, L-L\u00f3pez F, et al. Splicing machinery dysregulation drives glioblastoma development\/aggressiveness: oncogenic role of SRSF3. Brain J Neurol. 2020;143:3273\u201393.","journal-title":"Brain J Neurol"},{"key":"911_CR54","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet Lond Engl. 2020;395:817\u201327.","journal-title":"Lancet Lond Engl"},{"key":"911_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrc1011","volume":"3","author":"Y Shiloh","year":"2003","unstructured":"Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3:155\u201368.","journal-title":"Nat Rev Cancer"},{"key":"911_CR56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1078-0432.CCR-18-1999","volume":"25","author":"M Ameratunga","year":"2019","unstructured":"Ameratunga M, Kipps E, Okines AFC, Lopez JS. To Cycle or Fight-CDK4\/6 Inhibitors at the Crossroads of Anticancer Immunity. Clin Cancer Res J Am Assoc Cancer Res. 2019;25:21\u20138.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"911_CR57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/gutjnl-2020-322744","volume":"71","author":"X Sun","year":"2022","unstructured":"Sun X, He X, Zhang Y, Hosaka K, Andersson P, Wu J, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut. 2022;71:129\u201347.","journal-title":"Gut"},{"key":"911_CR58","doi-asserted-by":"publisher","first-page":"e37460","DOI":"10.1097\/MD.0000000000037460","volume":"103","author":"H Ren","year":"2024","unstructured":"Ren H, Yang X, Hou W, Meng J, Luo D, Zhang C. Comprehensive analysis of the clinical and biological significances for chemokine CXCL3 in cholangiocarcinoma. Med (Balt). 2024;103:e37460.","journal-title":"Med (Balt)"},{"key":"911_CR59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gendis.2021.08.004","volume":"9","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Lan T, Wei Y, Wei X. CCL5\/CCR5 axis in human diseases and related treatments. Genes Dis. 2021;9:12\u201327.","journal-title":"Genes Dis"},{"key":"911_CR60","first-page":"244","volume":"8","author":"F Mohammad Rezaei","year":"2019","unstructured":"Mohammad Rezaei F, Hashemzadeh S, Ravanbakhsh Gavgani R, Hosseinpour Feizi M, Pouladi N, Samadi Kafil H, et al. Dysregulated KDR and FLT1 Gene Expression in Colorectal Cancer Patients. Rep. Biochem Mol Biol. 2019;8:244\u201352.","journal-title":"Rep. Biochem Mol Biol"},{"key":"911_CR61","unstructured":"Ottawa Hospital Research Institute. A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of PRMT5 Inhibitor, GSK3326595. Early Stage Breast Cancer. 2022. https:\/\/clinicaltrials.gov\/study\/NCT04676516"},{"key":"911_CR62","unstructured":"Janssen Research & Development, LLC. A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5). Subjects Adv Cancers. 2025 https:\/\/clinicaltrials.gov\/study\/NCT03573310"},{"key":"911_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrc1251","volume":"4","author":"MA Hollingsworth","year":"2004","unstructured":"Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4:45\u201360.","journal-title":"Nat Rev Cancer"},{"key":"911_CR64","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41587-023-01984-5","volume":"42","author":"R Beatson","year":"2024","unstructured":"Beatson R, Burchell JM. A mucin degrader for cancer therapy. Nat Biotechnol. 2024;42:572\u20133.","journal-title":"Nat Biotechnol"},{"key":"911_CR65","first-page":"671","volume":"38","author":"S Kumar","year":"2017","unstructured":"Kumar S, Cruz E, Joshi S, Patel A, Jahan R, Batra SK, et al. Genetic variants of mucins: unexplored conundrum. Carcinogenesis. 2017;38:671\u20139.","journal-title":"Carcinogenesis"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00911-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T18:02:34Z","timestamp":1750615354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00911-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["911"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00911-x","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors of the manuscript, have no relevant financial or non-financial interests to disclose, no competing interests to declare that are relevant to the content of this article, no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript and no financial or proprietary interests in any material discussed in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Medical University of Cordoba\/IMIBIC and Ethics Committees from all the Hospitals involved in the study (protocol code PI19\/01603, version 1 \u2013 13\/03\/2019). Informed consent was obtained through the Andalusian Biobank (Servicio Andaluz de Salud), from all individual participants included in the study and all of them are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}